702 related articles for article (PubMed ID: 31115724)
21. OCT2 expression in histiocytoses.
Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
[TBL] [Abstract][Full Text] [Related]
22. Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.
Salama HA; Jazieh AR; Alhejazi AY; Absi A; Alshieban S; Alzahrani M; Alaskar A; Gmati G; Damlaj M; Abuelgasim KA; Alghamdi A; Alahmari B; Almugairi A; Alzahrani H; Bazarbachi A; Musa MOH; Goyal G
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e66-e75. PubMed ID: 32943371
[TBL] [Abstract][Full Text] [Related]
23. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary histiocytosis: beyond Langerhans cell histiocytosis related to smoking.
Gallego CT; Bueno J; Cruces E; Stelow EB; Mancheño N; Flors L
Radiologia (Engl Ed); 2019; 61(3):215-224. PubMed ID: 30686482
[TBL] [Abstract][Full Text] [Related]
25. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
26. Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms.
Rech KL; He R
J Natl Compr Canc Netw; 2021 Nov; 19(11):1305-1311. PubMed ID: 34781270
[TBL] [Abstract][Full Text] [Related]
27. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
28. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
29. Histopathological and Clinical Findings in Cutaneous Manifestation of Erdheim-Chester Disease and Langerhans Cell Histiocytosis Overlap Syndrome Associated With the BRAFV600E Mutation.
Liersch J; Carlson JA; Schaller J
Am J Dermatopathol; 2017 Jul; 39(7):493-503. PubMed ID: 27898473
[TBL] [Abstract][Full Text] [Related]
30. Molecular and clinicopathologic characterization of pediatric histiocytoses.
Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
[TBL] [Abstract][Full Text] [Related]
31. [Combined histiocytosis of the Langerhans group (Langerhans cell histiocytosis and Erdheim-Chester disease) in a 64-year-old man with BRAF and NRAS mutations: a case report].
Rodríguez-Duque MS; Martín Soler P; González Vela MC; Gómez Román JJ
Rev Esp Patol; 2023; 56(3):186-190. PubMed ID: 37419557
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
[TBL] [Abstract][Full Text] [Related]
33. Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.
Arceci RJ
Am Soc Clin Oncol Educ Book; 2014; ():e441-5. PubMed ID: 24857137
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
Aaroe A; Kurzrock R; Goyal G; Goodman AM; Patel H; Ruan G; Ulaner G; Young J; Li Z; Dustin D; Go RS; Diamond EL; Janku F
Blood Adv; 2023 Aug; 7(15):3984-3992. PubMed ID: 36857436
[TBL] [Abstract][Full Text] [Related]
36. [Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].
Morimoto A; Sakamoto K; Kudo K; Shioda Y
Rinsho Shinkeigaku; 2024 Feb; 64(2):85-92. PubMed ID: 38281751
[TBL] [Abstract][Full Text] [Related]
37. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
38. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
39. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
Haroun F; Millado K; Tabbara I
Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
[TBL] [Abstract][Full Text] [Related]
40. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]